Compare OCSL & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | IVA |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2007 | 2020 |
| Metric | OCSL | IVA |
|---|---|---|
| Price | $13.15 | $4.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $12.63 | ★ $16.20 |
| AVG Volume (30 Days) | 560.2K | ★ 671.3K |
| Earning Date | 05-05-2026 | 03-30-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | $751.20 |
| P/E Ratio | $65.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $3.35 |
| 52 Week High | $14.31 | $7.98 |
| Indicator | OCSL | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 57.98 |
| Support Level | $12.31 | $4.46 |
| Resistance Level | $13.39 | $4.94 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 90.64 | 65.31 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.